Skip to main content
. 2018 Nov 21;51(3):1128–1134. doi: 10.4143/crt.2018.379

Fig. 1.

Fig. 1.

Progression-free survival (PFS) (A) and overall survival (OS) (B) with simvastatin plus XELOX and bevacizumab in metastatic colorectal cancer patients.